Please provide your email address to receive an email when new articles are posted on . PARIS — The new Hydrus stent from Ivantis provides effective IOP control with a safe, minimally invasive, ab ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Two-year results of the HORIZON study show that 77.2% of patients implanted with a Hydrus ...

CHICAGO -- For the first time in a multicenter randomized trial, minimally invasive glaucoma surgery (MIGS) with an intracanalicular (Schlemm's canal) stent significantly reduced long-term vision loss ...

CORONADO, California — In glaucoma patients, the implantation of an intracanalicular microstent (Hydrus, Ivantis) maintains low intraocular pressure for 2 years and reduces the need for medication, a ...

Thomas W. Samuelson, M.D., glaucoma specialist with Minnesota Eye Consultants, served as the HYDRUS I trial's medical monitor Click here for high-resolution version The Hydrus stent is one of several ...

CLEVELAND, Ohio -- Until this century, patients with increased eye pressure - a condition that can damage the eye if left untreated - faced surgery that involved a long incision and longer healing ...

The Hydrus Microstent is about the size of an eyelash.--Courtesy of Ivantis Ivantis' eyelash-sized eye stent helped lower intraocular pressure after one year in patients who have undergone cataract ...

AAO: Microstent Cuts Intraocular Pressure in Glaucoma For patients with mild-to-moderate open-angle glaucoma, implantation of a nickel titanium microstent (Hydrus Microstent) is associated with ...

ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday. Privately held Ivantis ...

CHICAGO – November 13, 2012 – A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to ...